1. The new coronavirus antibody test is positive, and the new coronavirus nucleic acid test is positive, 2. Have a history of SARS/MERS virus infection (self-report, on-site inquiry), 3. Have been vaccinated against other novel coronavirus vaccines, 4. Those who have a history of allergy to phenol and Mamemin, 5. Women with positive urine pregnancy test, pregnant, breastfeeding, or women planning to become pregnant within 12 months, 6. Those with a medical history or family history of allergies, convulsions, epilepsy, encephalopathy and mental illness, 7. Any history of allergy to drugs or vaccinations (such as acute allergic reaction, urticaria, skin eczema, dyspnea, angioedema or abdominal pain) or allergy to known components of the new coronavirus vaccine, 8. Severe cardiovascular disease diagnosed by the hospital (cardiopulmonary failure, hypertension that cannot be controlled by drugs, etc.), 9. History of thrombocytopenia or other coagulation disorders diagnosed by the hospital, 10. Those who have received whole blood, plasma and immunoglobulin therapy within 3 months, 11. Patients with clinically significant abnormalities in blood biochemistry, blood routine, and urine routine related indexes detected before vaccination in Phase I clinical study, 12. Those with symptoms of fever (axillary temperature>37.3?), dry cough, fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath and dyspnea within 14 days before vaccination, 13. Received live attenuated vaccine within 1 month before vaccination, and received other vaccines within 14 days before vaccination, 14. Those with axillary body temperature >37.3? during vaccination, 15. Contraindications related to vaccination in the opinion of the investigator.

1. The new coronavirus antibody test is positive, and the new coronavirus nucleic acid test is positive, 2. Have a history of SARS/MERS virus infection (self-report, on-site inquiry), 3. Have been vaccinated against other novel coronavirus vaccines, 4. Those who have a history of allergy to phenol and Mamemin, 5. Women with positive urine pregnancy test, pregnant, breastfeeding, or women planning to become pregnant within 12 months, 6. Those with a medical history or family history of allergies, convulsions, epilepsy, encephalopathy and mental illness, 7. Any history of allergy to drugs or vaccinations (such as acute allergic reaction, urticaria, skin eczema, dyspnea, angioedema or abdominal pain) or allergy to known components of the new coronavirus vaccine, 8. Severe cardiovascular disease diagnosed by the hospital (cardiopulmonary failure, hypertension that cannot be controlled by drugs, etc.), 9. History of thrombocytopenia or other coagulation disorders diagnosed by the hospital, 10. Those who have received whole blood, plasma and immunoglobulin therapy within 3 months, 11. Patients with clinically significant abnormalities in blood biochemistry, blood routine, and urine routine related indexes detected before vaccination in Phase I clinical study, 12. Those with symptoms of fever (axillary temperature>37.3?), dry cough, fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath and dyspnea within 14 days before vaccination, 13. Received live attenuated vaccine within 1 month before vaccination, and received other vaccines within 14 days before vaccination, 14. Those with axillary body temperature >37.3? during vaccination, 15. Contraindications related to vaccination in the opinion of the investigator.

1. The Novel Coronavirus Pneumonia antibody is positive or Novel Coronavirus Pneumonia nucleic acid test is positive, 2. Subjects with Infection history of SARS / MRES virus, 3. Subjects contacted with Novel Coronavirus Pneumonia cases or suspected cases in one month, 4. Subjects have inoculated other Novel Coronavirus Pneumonia vaccines, 5. Subjects with sensitive history of phenmethamine, 6. Female subjects are pregnant at the time of admission (positive reaction in urine pregnancy test), lactation or have a family planning within 12 months, 7. Subjects with history of convulsion, epilepsy, Guillain Barre syndrome, encephalopathy or mental illness or family history, 8. Subjects with history of severe allergic reactions (such as anaphylactic shock, acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known composition of vaccine, 9. Subjects with known severe cardiovascular diseases, 10. Subjects diagnosed with thrombocytopenia or other coagulation disorders, 11. Subjects receiving blood products within 3 months before administration, 12. Subjects with abnormal indicators, such as blood biochemistry, blood routine and urine routine, which might show clinical meaning before administration, 13. Subjects with fever (axillary temperature > 37.3 degree C), cough, fatigue, nasal obstruction, pharyngalgia, muscle pain, diarrhea, and dyspnea occurred within 14 days before inoculation, 14. Subjects vaccinated with attenuated vaccine within 1 month, or other vaccine within 14 days before vaccination. 15. Armpit temperature > 37.0 ? at the time of vaccination, 16. The researchers shall judge the other conditions which might be not in compliance with this clinical trial.

1. The Novel Coronavirus Pneumonia antibody is positive or Novel Coronavirus Pneumonia nucleic acid test is positive, 2. Subjects with Infection history of SARS / MRES virus, 3. Subjects contacted with Novel Coronavirus Pneumonia cases or suspected cases in one month, 4. Subjects have inoculated other Novel Coronavirus Pneumonia vaccines, 5. Subjects with sensitive history of phenmethamine, 6. Female subjects are pregnant at the time of admission (positive reaction in urine pregnancy test), lactation or have a family planning within 12 months, 7. Subjects with history of convulsion, epilepsy, Guillain Barre syndrome, encephalopathy or mental illness or family history, 8. Subjects with history of severe allergic reactions (such as anaphylactic shock, acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known composition of vaccine, 9. Subjects with known severe cardiovascular diseases, 10. Subjects diagnosed with thrombocytopenia or other coagulation disorders, 11. Subjects receiving blood products within 3 months before administration, 12. Subjects with abnormal indicators, such as blood biochemistry, blood routine and urine routine, which might show clinical meaning before administration, 13. Subjects with fever (axillary temperature > 37.3 degree C), cough, fatigue, nasal obstruction, pharyngalgia, muscle pain, diarrhea, and dyspnea occurred within 14 days before inoculation, 14. Subjects vaccinated with attenuated vaccine within 1 month, or other vaccine within 14 days before vaccination. 15. Armpit temperature > 37.0 ? at the time of vaccination, 16. The researchers shall judge the other conditions which might be not in compliance with this clinical trial.